article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

Targeting GPCRs to fight inflammatory diseases GPCR-targeting drugs are well known therapies for a range of disease types, including cardio-metabolic, central nervous system and endocrinological disorders. It also holds potential for neuroinflammatory conditions such as certain types of migraine.

Disease 59
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Consider drugs targeting rare diseases or specialized conditions. Biosimilars and Complex Generics The rise of biosimilars and complex generics is changing the dynamics of market exclusivity. Staying informed about future trends, such as biosimilars and personalized medicine, is crucial for adapting strategies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%

article thumbnail

Bio-Techne Joins Forces with USP to Speed Up Development of mAbs and Gene Therapies

The Pharma Data

Biologic drugs, including monoclonal antibodies, have become essential in the treatment of a wide array of conditions, from autoimmune diseases to various cancers. To date, more than 160 monoclonal antibody therapies targeting nearly 100 disease-related proteins have received regulatory approval globally.

article thumbnail

Déjà Vu: OPDP Again Targets Provider Branded Website of Accelerated Approval Drug in Second Untitled Letter of 2025

FDA Law Blog: Biosimilars

no comparator arm), FOENIX-CCA2 was not capable of establishing improvement on time-to-event efficacy endpoints such as PFS or OS and, without an appropriate comparator, it is not possible to determine if the observed effect is attributable to LYTGOBI or to other factor(s), such as the natural history of the disease.

Drugs 52
article thumbnail

The MAHA Assessment’s Implications: Drugs (Part One)

FDA Law Blog: Biosimilars

The Strategy must address appropriately restructuring the Federal Governments response to the childhood chronic disease crisis, including by ending Federal practices that exacerbate the health crisis or unsuccessfully attempt to address it, and by adding powerful new solutions that will end childhood chronic disease.

Drugs 59
article thumbnail

Building the requisite clinical development infrastructure for medical innovation to thrive

Drug Target Review

Innovations like gene therapies are providing hope for diseases that previously had no treatment options, while precision medicine such as cell therapy personalises treatments to fit each patients signature biological characteristics. No longer can we rely on outdated methodologies that stifle potential.